Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022

The global PDX models market is expected to reach to USD 167.6 Million by 2022 from USD 68.0 Million in 2016 at a CAGR of 16.7%. The growth of the overall Patient Derived Xenograft Models Market can be attributed to the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. In the coming years, North America is expected to account for the largest share of the global market. Base year considered for the report is 2016 and the forecast period includes 2017–2022.

Objectives of the Study:

• To define, describe, and measure the global Patient Derived Xenograft (PDX) models market by model type, tumor type, application, end user, and region
• To provide detailed information regarding the major factors, such as drivers, restraints, growth opportunities, and challenges influencing the growth of the market
• To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the global PDX models market
• To analyze the opportunities in the global patient derived xenograft models market for key stakeholders and provide details of the competitive landscape for major market leaders
• To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific (APAC), and the Rest of the World
• To strategically analyze the market structure and profile the key players of the global PDX models market and comprehensively analyze their core competencies
• To benchmark players within the market using proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
• To track and analyze competitive developments such as partnerships, agreements, alliances, joint ventures, collaborations, product launches, expansions, acquisitions, grants/funds, and licensing agreements, among others in the patient derived xenograft models market.

Research Methodology

Top-down and bottom-up approaches were used to validate the size of the global PDX models market and estimate the size of other dependent submarkets. Various secondary sources such as the American Association for Cancer Research (AACR), American Veterinary Medical Association (AVMA), American Association for Laboratory Animal Science (AALAS), South Texas Accelerated Research Therapeutics (START), Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), European Medicines Agency (EMA), EurOPDX, European Animal Research Association (EARA), European Society For Medical Oncology (ESMO), European Association for Cancer Research (EACR), European Journal of Cancer (EJC), Federation for Laboratory Animal Science Associations (FELESA), Medical Research Council (MRC), Swiss Laboratory Animal Science Association (SGV), European Organization for Research and Treatment of Cancer (EORTC), Italian Association for Cancer Research (AIRC), Animal Technology Institute Taiwan (ATIT), Asian Mouse Mutagenesis Resource Association (AMMRA), Australian Phenomics Network (APN), Sao Paulo Research Foundation (FAPESP), South African Association for Laboratory Animal Science (SAALAS), directories, industry journals, databases, and annual reports of the companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this market. The breakdown of profiles of primaries is shown in the figure below:

To know about the assumptions considered for the study, download the pdf brochure

The various players in the PDX models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).

Target Audience:

• Mice/rat models and service companies and distributors
• Animal care product manufacturers and suppliers
• Out–licensing life sciences companies (pharmaceutical/biopharmaceutical/biotechnology)
• In–licensing life sciences companies (pharmaceutical/biopharmaceutical/biotechnology)
• Clinical research organizations
• Academic institutes
• Government and private research institutes
• Medical research centers
• Public and private animal health agencies
• Animal care associations
• Business consultancies
• Venture capitalists

Scope of the report:

The research report categorizes the patient derived xenograft models market into the following segments and subsegments:

PDX Models Market, by Type           

• Mice Models
• Rat Models

PDX Models Market, by Tumor Type

• Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors)
• Gynecological Tumor Models (breast, ovarian, and cervical tumors)
• Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors)
• Urological Tumor Models (renal, prostate, and bladder tumors)
• Hematological Tumor Models (leukemia and lymphoma)
• Other Tumor Models (head & neck cancer, sarcoma, and melanoma)

PDX Models Market, by Application

• Pre-clinical Drug Development and Basic Cancer Research
• Biomarker Analysis

PDX Models Market, by End User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions

PDX Models Market, by Region

• North America
  • US
  • Canada
• Europe
• Asia Pacific
• Rest of the World (RoW)

Available customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Portfolio Analysis

• Product Matrix, which gives a detailed comparison of the product portfolio of each company

Company Information

• Detailed analysis and profiling of additional market players (Up to 5)

Table of Contents

1 Introduction (Page No. - 12)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 16)
    2.1 Research Methodology Steps
    2.2 Secondary and Primary Research Methodology
           2.2.1 Secondary Research
                    2.2.1.1 Key Data From Secondary Sources
           2.2.2 Primary Research
                    2.2.2.1 Key Industry Insights
                    2.2.2.2 Key Data From Primary Sources
                    2.2.2.3 Key Insights From Primary Sources
    2.3 Market Size Estimation Methodology
    2.4 Market Forecast Methodology
    2.5 Market Data Validation and Triangulation
    2.6 Assumptions

3 Executive Summary (Page No. - 26)

4 Premium Insights (Page No. - 30)
    4.1 PDX Models Market Overview
    4.2 Regional Analysis: Global Patient Derived Xenograft Models Market, By End User
    4.3 Global PDX Models Market, By Tumor Type, 2017 & 2022
    4.4 Regional Snapshot of the Global Patient Derived Xenograft Models Market

5 Market Overview (Page No. - 34)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Growing Demand for Personalized Medicine
                    5.2.1.2 Continuous Support for Cancer Research From Public as Well as Private Sector
                    5.2.1.3 Growth in the Number of Pharmaceutical R&D Activities
           5.2.2 Restraints
                    5.2.2.1 High Cost of Personalized PDX Models
                    5.2.2.2 Stringent Guidelines for the Use of Animal Models in Cancer Research
           5.2.3 Opportunity
                    5.2.3.1 Rising Demand for Humanized PDX Models
           5.2.4 Challenge
                    5.2.4.1 Limitations of PDX Models

6 Patient Derived Xenograft Models Market, By Type (Page No. - 40)
    6.1 Introduction
    6.2 Mice Models
    6.3 Rat Models

7 Patient Derived Xenograft Models Market, By Tumor Type (Page No. - 44)
    7.1 Introduction
    7.2 Gastrointestinal Tumor Models
    7.3 Gynecological Tumor Models
    7.4 Respiratory Tumor Models
    7.5 Urological Tumor Models
    7.6 Hematological Tumor Models
    7.7 Other Tumor Models

8 Patient Derived Xenograft Models Market, By Application (Page No. - 52)
    8.1 Introduction
    8.2 Preclinical Drug Development and Basic Cancer Research
    8.3 Biomarker Analysis

9 Patient Derived Xenograft Models Market, By End User (Page No. - 56)
    9.1 Introduction
    9.2 Pharmaceutical & Biotechnology Companies
    9.3 Contract Research Organizations
    9.4 Academic & Research Institutions

10 Patient Derived Xenograft Models Market, By Region (Page No. - 62)
     10.1 Introduction
     10.2 North America
             10.2.1 US
                        10.2.1.1 Growing Focus on Cancer Research in the US
                        10.2.1.2 Rise in Mab Production
                        10.2.1.3 Development of Oncology Biosimilars Boosting the Demand for Preclinical Services
             10.2.2 Canada
                        10.2.2.1 Rising Stem Cell Research
     10.3 Europe
             10.3.1 Focus on Cancer Research and Treatment
             10.3.2 Germany: Growth of the Biotech Sector
             10.3.3 Spain: Availability of Venture Funding for Life Sciences
             10.3.4 Italy: Growth of the Biotech, Pharma Sectors
             10.3.5 Rising Research Investments in Sweden, Austria, and Denmark
     10.4 Asia Pacific
             10.4.1 Rising Focus on Precision Medicine and Personalized Medicine in China
             10.4.2 Strong Research Expenditure and Well-Structured Cros Industry in China
             10.4.3 Growing Focus of Pharmaceutical and Animal Research Model Suppliers on China
             10.4.4 Public and Private Investments in China’s Life Sciences Sector
             10.4.5 Initiatives to Reduce Long Approval Times in China
             10.4.6 Intellectual Property (Ip) Breaches, A Challenge for Market Growth in China
             10.4.7 Japan: Growth in Biomedical and Medical Research
             10.4.8 India: Rising R&D Expenditure
             10.4.9 Infrastructural Limitations in India
             10.4.10 Availability of Funding for Biomedical Research in Australia
             10.4.11 Rising Translational and Biomedical Research in SingAPOre
             10.4.12 Rising Pharmaceutical and Biotechnology R&D in Korea
     10.5 Rest of the World (RoW)
             10.5.1 Rising R&D in Brazil
             10.5.2 Growth of the Pharmaceutical and Biotechnology Industries in Saudi Arabia and the UAE

11 Competitive Landscape (Page No. - 89)
     11.1 Introduction
     11.2 Market Ranking Analysis
     11.3 Competitive Leadership Mapping
             11.3.1 Visionary Leaders
             11.3.2 Innovators
             11.3.3 Emerging Companies
             11.3.4 Dynamic Differentiators
     11.4 Competitive Benchmarking
             11.4.1 Strength of Product Portfolio
             11.4.2 Business Strategy Excellence

*Top 15 companies analyzed for this studies are - Crown Bioscience Inc. (US), Champions Oncology, Inc. (US), The Jackson Laboratory (US), Charles River Laboratories, International, Inc. (US), WuXi AppTec (China), ONCODESIGN (France), EPO Berlin-Buch GmbH   (Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Pharmatest Services Ltd. (Finland), Hera BioLabs (US), Urolead (France), Xenopat (Spain), Bioduro (US)

12 Company Profiles (Page No. - 94)
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
     12.1 Crown Bioscience Inc.
     12.2 the Jackson Laboratory
     12.3 Champions Oncology, Inc.
     12.4 Charles River Laboratories International, Inc.
     12.5 WuXi Apptec (Group of Subsidiaries Under WuXi Pharmatec)
     12.6 ONCODESIGN
     12.7 Horizon Discovery Group PLC  (Sage Labs, Inc.)
     12.8 Pharmatest Services Ltd.
     12.9 Hera Biolabs
     12.10 EPO Berlin-Buch GmbH
     12.11 Xentech
     12.12 Urolead

*Details on Marketsandmarkets View, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 140)
     13.1 Discussion Guide
     13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.3 Introducing RT: Real-Time Market Intelligence
     13.4 Available Customizations
     13.5 Related Reports
     13.6 Author Details

List of Tables (44 Tables)

Table 1 Global PDX Models Market, By Type, 2015–2022 (USD Million)
Table 2 PDX Mice Models Market, By Region, 2015–2022 (USD Million)
Table 3 PDX Rat Models Market, By Region, 2015–2022 (USD Thousand)
Table 4 Global Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 5 Gastrointestinal Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 6 Gynecological Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 7 Respiratory Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 8 Urological Tumor Models Market, By Region, 2015–2022 (USD Thousand)
Table 9 Hematological Tumor Models Market, By Region, 2015–2022 (USD Thousand)
Table 10 Other Tumor Models Market, By Region, 2015–2022 (USD Million)
Table 11 Global PDX Models Market, By Application, 2015–2022 (USD Million)
Table 12 Patient Derived Xenograft Models Market for Preclinical Drug Development and Basic Cancer Research, By Region, 2015–2022 (USD Million)
Table 13 PDX Models Market for Biomarker Analysis, By Region, 2015–2022 (USD Million)
Table 14 Global Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 15 PDX Models Market for Pharmaceutical & Biotechnology Companies, By Region, 2015–2022 (USD Million)
Table 16 PDX Models Market for Contract Research Organizations,  By Region, 2015–2022 (USD Million)
Table 17 Patient Derived Xenograft Models Market for Academic & Research Institutions, By Region, 2015–2022 (USD Million)
Table 18 Global Market, By Region, 2015–2022 (USD Million)
Table 19 North America: PDX Models Market, By Country, 2015-2022 (USD Million)
Table 20 North America: Patient Derived Xenograft Models Market, By Type, 2015–2022 (USD Million)
Table 21 North America: Market, By Tumor Type, 2015–2022 (USD Million)
Table 22 North America: Market, By Application, 2015–2022 (USD Million)
Table 23 North America: Market, By End User, 2015–2022 (USD Million)
Table 24 US: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 25 US: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 26 US: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 27 US: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 28 Canada: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 29 Canada: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 30 Canada: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 31 Canada: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 32 Europe: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 33 Europe: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 34 Europe: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 35 Europe: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 36 Japan: Significant Partnerships
Table 37 Asia Pacific: PDX Models Market, By Type, 2015–2022 (USD Million)
Table 38 Asia Pacific: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Million)
Table 39 Asia Pacific: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 40 Asia Pacific: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
Table 41 RoW: PDX Models Market, By Type, 2015–2022 (USD Thousand)
Table 42 RoW: Patient Derived Xenograft Models Market, By Tumor Type, 2015–2022 (USD Thousand)
Table 43 RoW: PDX Models Market, By Application, 2015–2022 (USD Million)
Table 44 RoW: Patient Derived Xenograft Models Market, By End User, 2015–2022 (USD Million)
 
 
List of Figures (34 Figures)
 
 
Figure 1 Global PDX Models Market: Research Methodology Steps
Figure 2 Sampling Frame: Primary Research
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market Size Estimation Methodology: Bottom-Up Approach
Figure 5 Market Size Estimation Methodology: Top-Down Approach
Figure 6 Market Forecast Methodology
Figure 7 Data Triangulation Methodology
Figure 8 Global PDX Models Market, By Type (2017)
Figure 9 Global Patient Derived Xenograft Models Market, By Tumor Type (2017)
Figure 10 Global PDX Models Market, By Application
Figure 11 Global Patient Derived Xenograft Models Market, By End User
Figure 12 Asia Pacific to Witness Highest Growth During the Forecast Period
Figure 13 Growing Cancer Research to Drive the Global PDX Models Market
Figure 14 North America is Expected to Dominate the Patient Derived Xenograft Models Market in 2017
Figure 15 Gastrointestinal Tumors to Account for the Largest Share of the Market in 2017
Figure 16 The Asia Pacific Region to Grow at the Highest CAGR During the Forecast Period
Figure 17 PDX Models Market: Drivers, Restraints, Opportunities, and Challenges
Figure 18 Mice Models to Dominate the Patient Derived Xenograft Models Market During the Forecast Period
Figure 19 Gastrointestinal Tumor Models is Expected to Account for the Largest Market Share in 2017
Figure 20 Preclinical Drug Development and Basic Cancer Research Applications to Dominate the PDX Models Market
Figure 21 Contract Research Organizations to Register the Highest CAGR During the Forecast Period
Figure 22 Asia Pacific to Grow at the Highest CAGR in the Patient Derived Xenograft Models Market
Figure 23 North America: PDX Models Market Snapshot
Figure 24 Europe: Patient Derived Xenograft Models Market Snapshot
Figure 25 Asia Pacific: PDX Models Market Snapshot
Figure 26 RoW: Patient Derived Xenograft Models Market Snapshot
Figure 27 Global PDX Model Market Ranking (As of 2016)
Figure 28 PDX Models Market (Global) Competitive Leadership Mapping,2017
Figure 29 The Jackson Laboratory: Company Snapshot (2016)
Figure 30 Champions Oncology, Inc.: Company Snapshot (2016)
Figure 31 Charles River Laboratories International, Inc.: Company Snapshot (2016)
Figure 32 WuXi Pharmatec: Company Snapshot (2015)
Figure 33 ONCODESIGN: Company Snapshot (2016)
Figure 34 Horizon Discovery Group PLC: Company Snapshot (2016) 

The global PDX models market is expected to reach USD 167.6 Million by 2022 from USD 77.4 Million in 2017, at a CAGR of 16.7%. The growth of this market is majorly driven by the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. However, the high cost of personalized PDX models and stringent guidelines regarding the ethical use of animals in cancer research are expected to restrain the growth of this market during the forecast period.

The report analyzes the patient derived xenograft models market by type, tumor type, application, end user, and region. On the basis of type, the market is segmented into mice and rat models. The mice models segment is estimated to command the largest share of the global market in 2017. The rat models segment, on the other hand, is projected to register the highest CAGR from 2017 to 2022. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. The development of immunodeficient rats will drive the usage of rat models in PDX model generation. Based on tumor type, the PDX models market has been segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017, the gastrointestinal tumor models segment is expected to account for the largest share of the global market.

Based on application, the PDX models market has been broadly segmented into preclinical drug development & basic cancer research and biomarker analysis. In 2017, the preclinical drug development and basic cancer research segment is expected to account for the largest share of the global patient derived xenograft models market. Growth in this segment is mainly driven by the increasing number of research activities in the field of oncology drug research. On the basis of end user, the PDX models market has been segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic & research institutions. The pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the patient derived xenograft models market in 2017. The large share of this segment is due to the increasing expenditure on R&D by companies for drug development.

Geographically, in 2017, North America is estimated to account for the largest share of the global PDX models market, followed by Europe. Growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada are the major factors expected to drive the growth of the market during the forecast period.

The various players in the patient derived xenograft models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst